Gyre Therapeutics, Inc. (GYRE)
Automate Your Wheel Strategy on GYRE
With Tiblio's Option Bot, you can configure your own wheel strategy including GYRE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GYRE
- Rev/Share 1.1646
- Book/Share 1.2069
- PB 10.1107
- Debt/Equity 0.0233
- CurrentRatio 3.6042
- ROIC 0.0945
- MktCap 719876701.0
- FreeCF/Share -0.1025
- PFCF -81.2502
- PE 49.3072
- Debt/Assets 0.0122
- DivYield 0
- ROE 0.2191
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | GYRE | Noble Capital Markets | -- | Outperform | -- | -- | March 11, 2025 |
News
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. In addition, Gyre has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 333,333 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Read More
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Q1 2025 revenue of $22.1 million; GAAP basic EPS: $0.03 Completed data collection and achieved database lock for the pivotal Phase 3 trial of Hydronidone in Chronic Hepatitis B (“CHB”)-associated liver fibrosis; currently reviewing data and on track to report topline results in Q2 2025 Received IND approval from China's National Medical Products Administration (“NMPA”) for a new indication of pirfenidone to treat radiation-induced lung injury (“RILI”), with or without immune-related pneumonitis (“CIP”), marking Gyre's first entry into oncology supportive care space Initiated commercialization of avatrombopag in China in March 2025, building a strategic presence with liver disease specialists Nintedanib …
Read More
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on organ fibrosis, today announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B: Protocol for a Phase 3 Randomized Trial” in the Journal of Clinical and Translational Hepatology. This publication details the full protocol for the pivotal Phase 3 trial to support the use of hydronidone in Chinese patients with liver fibrosis associated with chronic hepatitis B (“CHB”).
Read More
About Gyre Therapeutics, Inc. (GYRE)
- IPO Date 2006-04-12
- Website https://www.gyretx.com
- Industry Biotechnology
- CEO Dr. Han Ying Ph.D.
- Employees 579